Among patients with early diffuse cutaneous systemic sclerosis, HSCT was associated with increased treatment-related mortality in the first year after treatment. However, HCST conferred a significant long-term event-free survival benefit. JAMA, 2014;311(24):2490-2498. (Also see: Stem Cell Transplantation and Cyclophosphamide Research)
This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.